{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T09:10:47Z","timestamp":1721380247476},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNCI J Natl Cancer Inst"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1093\/jnci\/djw155","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T03:49:19Z","timestamp":1467949759000},"page":"djw155","source":"Crossref","is-referenced-by-count":5,"title":["RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw"],"prefix":"10.1093","volume":"108","author":[{"given":"Vittorio","family":"Fusco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmauro","family":"Numico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A.","family":"Migliorati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"2016070720490767000_108.9.djw155.1","doi-asserted-by":"crossref","unstructured":"Antonuzzo L Lunghi A Giommoni E Brugia M Di Costanzo F. Regorafenib Also Can Cause Osteonecrosis of the Jaw. J Natl Cancer Inst. 2016;108(4). Doi: 10.1093\/jnci\/djw002.","DOI":"10.1093\/jnci\/djw002"},{"key":"2016070720490767000_108.9.djw155.2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.211"},{"key":"2016070720490767000_108.9.djw155.3","unstructured":"FDA report on aflibercept: Center for drug evaluation and research. Application number 125418Orig1s000. Clinical Review. Aflibercept \/ Zaltrap. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125418Orig1s000MedR.pdf. Accessed May 17, 2016."},{"key":"2016070720490767000_108.9.djw155.4","doi-asserted-by":"crossref","unstructured":"Ponzetti A Pinta F Spadi R , . Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori. 2015; in press.","DOI":"10.5301\/tj.5000405"},{"key":"2016070720490767000_108.9.djw155.5","doi-asserted-by":"crossref","unstructured":"Fusco V Bedogni A Addeo A Campisi G. Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study? Support Care Cancer. 2016; in press.","DOI":"10.1007\/s00520-016-3147-9"}],"container-title":["Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/108\/9\/djw155\/18077819\/djw155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T13:14:29Z","timestamp":1503580469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djw155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":5,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,7,7]]},"published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1093\/jnci\/djw155"],"URL":"https:\/\/doi.org\/10.1093\/jnci\/djw155","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}